Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
177Lu-PSMA radioligand therapy in oligometastatic hormone-sensitive prostate cancer
NL-OMON52656Phase 2Recruiting
- Sponsor
- Radboud University Medical Center
- Start
- Jul 2020
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of lutetium lu 177 vipivotide tetraxetan in prostate adenocarcinoma and prostate cancer (PCa) (2 arms), sponsored by Radboud University Medical Center. Primary endpoint: Disease progression within 6 months. Started Jul 2020; status: recruiting.
02
Drugs
lutetium lu 177 vipivotide tetraxetan
03
Conditions
prostate adenocarcinomaprostate cancer (PCa)
Beyond the preview
Go deeper on NL-OMON52656.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52656.